Article
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
Cancer - 15 Sept 2017
McWilliams Robert R, Foster Nathan R, Mahoney Michelle R, Smyrk Thomas C, Murray Joseph A, Ames Matthew M, Horvath L Elise, Schneider Daniel J, Hobday Timothy J, Jatoi Aminah, Meyers Jeffrey P, Goetz Matthew P
Abstract excerpt
BACKGROUND: Oxaliplatin in combination with either 5-fluorouracil or capecitabine is commonly used as first-line therapy for patients with small bowel adenocarcinoma. The addition of irinotecan improves survival in other gastrointestinal tumors but at the cost of hematologic toxicity. The authors performed a phase 2 cooperative group study (North Central Cancer Treatment Group N0543, Alliance) using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.